We've detected that Javascript is not enabled. It is required for an optimal survey taking experience.
Please check your browser's settings and make sure Javascript is turned on. Learn how to enable Javascript.

Skip survey header

2020 ASPHO/COG Joint Session Evaluation: Recent Advances in Pediatric and AYA Lymphomas

1. Name and Credentials (as you would like it to appear on your CME certificate): *This question is required.

2. E-mail Address: *This question is required. This question requires a valid email address.

3. How valuable was the content of this session for you? *This question is required.

4. Objectives:

Discuss the opportunities for enrolling both pediatric and adolescent and young adult patients on risk adapted therapeutic trials for Hodgkin’s and non-Hodgkin’s lymphomas.
Explain the results of pivotal trials, in relapsed/refractory Hodgkin’s lymphoma and newly diagnosed anaplastic large cell lymphoma, designed to establish the safety and preliminary efficacy of checkpoint inhibitors, antibody drug conjugates and ALK inhibition.
Describe the importance of PD-1 mutations in the pathogenesis of lymphomas and the safety and efficacy of checkpoint inhibition in the treatment of Hodgkin’s and non-Hodgkin’s lymphomas.
Recognize the early success of cellular therapies as well as the current and coming indications for these therapies for patients with Hodgkin’s and non-Hodgkin’s lymphomas.

Rate your level of agreement with the following statement.

Presenters met stated learning objectives: *This question is required.

5. Speaker Evaluation
Please rate your level of agreement for each speaker on the following:

Presenter was effective *This question is required.

Space Cell	Strongly Agree	Moderately Agree	Neither Agree nor Disagree	Moderately Disagree	Strongly Disagree	N/A
Lisa Roth, MD	Lisa Roth, MD: Strongly Agree	Lisa Roth, MD: Moderately Agree	Lisa Roth, MD: Neither Agree nor Disagree	Lisa Roth, MD: Moderately Disagree	Lisa Roth, MD: Strongly Disagree	Lisa Roth, MD: N/A
Eric Lowe, MD	Eric Lowe, MD: Strongly Agree	Eric Lowe, MD: Moderately Agree	Eric Lowe, MD: Neither Agree nor Disagree	Eric Lowe, MD: Moderately Disagree	Eric Lowe, MD: Strongly Disagree	Eric Lowe, MD: N/A
Paul Harker-Murray, MD, PhD	Paul Harker-Murray, MD, PhD : Strongly Agree	Paul Harker-Murray, MD, PhD : Moderately Agree	Paul Harker-Murray, MD, PhD : Neither Agree nor Disagree	Paul Harker-Murray, MD, PhD : Moderately Disagree	Paul Harker-Murray, MD, PhD : Strongly Disagree	Paul Harker-Murray, MD, PhD : N/A
Nita Seibel, MD	Nita Seibel, MD : Strongly Agree	Nita Seibel, MD : Moderately Agree	Nita Seibel, MD : Neither Agree nor Disagree	Nita Seibel, MD : Moderately Disagree	Nita Seibel, MD : Strongly Disagree	Nita Seibel, MD : N/A
Jonathan Friedberg, MD, M.M. Sc	Jonathan Friedberg, MD, M.M. Sc : Strongly Agree	Jonathan Friedberg, MD, M.M. Sc : Moderately Agree	Jonathan Friedberg, MD, M.M. Sc : Neither Agree nor Disagree	Jonathan Friedberg, MD, M.M. Sc : Moderately Disagree	Jonathan Friedberg, MD, M.M. Sc : Strongly Disagree	Jonathan Friedberg, MD, M.M. Sc : N/A
Helen Heslop, MD	Helen Heslop, MD : Strongly Agree	Helen Heslop, MD : Moderately Agree	Helen Heslop, MD : Neither Agree nor Disagree	Helen Heslop, MD : Moderately Disagree	Helen Heslop, MD : Strongly Disagree	Helen Heslop, MD : N/A

6. Presenter demonstrated expertise in the content area they presented on *This question is required.

Space Cell	Strongly Agree	Moderately Agree	Neither Agree nor Disagree	Moderately Disagree	Strongly Disagree	N/A
Lisa Roth, MD	Lisa Roth, MD: Strongly Agree	Lisa Roth, MD: Moderately Agree	Lisa Roth, MD: Neither Agree nor Disagree	Lisa Roth, MD: Moderately Disagree	Lisa Roth, MD: Strongly Disagree	Lisa Roth, MD: N/A
Eric Lowe, MD	Eric Lowe, MD: Strongly Agree	Eric Lowe, MD: Moderately Agree	Eric Lowe, MD: Neither Agree nor Disagree	Eric Lowe, MD: Moderately Disagree	Eric Lowe, MD: Strongly Disagree	Eric Lowe, MD: N/A
Paul Harker-Murray, MD, PhD	Paul Harker-Murray, MD, PhD : Strongly Agree	Paul Harker-Murray, MD, PhD : Moderately Agree	Paul Harker-Murray, MD, PhD : Neither Agree nor Disagree	Paul Harker-Murray, MD, PhD : Moderately Disagree	Paul Harker-Murray, MD, PhD : Strongly Disagree	Paul Harker-Murray, MD, PhD : N/A
Nita Seibel, MD	Nita Seibel, MD : Strongly Agree	Nita Seibel, MD : Moderately Agree	Nita Seibel, MD : Neither Agree nor Disagree	Nita Seibel, MD : Moderately Disagree	Nita Seibel, MD : Strongly Disagree	Nita Seibel, MD : N/A
Jonathan Friedberg, MD, M.M. Sc	Jonathan Friedberg, MD, M.M. Sc : Strongly Agree	Jonathan Friedberg, MD, M.M. Sc : Moderately Agree	Jonathan Friedberg, MD, M.M. Sc : Neither Agree nor Disagree	Jonathan Friedberg, MD, M.M. Sc : Moderately Disagree	Jonathan Friedberg, MD, M.M. Sc : Strongly Disagree	Jonathan Friedberg, MD, M.M. Sc : N/A
Helen Heslop, MD	Helen Heslop, MD : Strongly Agree	Helen Heslop, MD : Moderately Agree	Helen Heslop, MD : Neither Agree nor Disagree	Helen Heslop, MD : Moderately Disagree	Helen Heslop, MD : Strongly Disagree	Helen Heslop, MD : N/A

7. The session was scientifically rigorous, balanced, and free of commercial bias.

8. As a result of attending this session, describe one to two changes you intend to make in your practice. *This question is required.

9. Other comments regarding the session: